The big-data revolution is creating a challenge for the provision of services in the health sector to keep pace with the expectations of the general population. Utilization of crowdsourcing can impact positively on the quality, cost and speed of healthcare by involving large sections of professionals and the public and creating novel science within an ethical framework. In 2007, the DYSCERNE project was funded by the European Commission Public Health Executive Agency (EU DG Sanco) aimed at setting up a network of expertise for rare dysmorphic disorders. As part of DYSCERNE, a Dysmorphology Diagnostic System was set up to enable clinicians throughout the EU to submit cases electronically for diagnosis using a secure, web-based interface, hosted at specified access points (submitting nodes), in 26 different European countries. DYSCERNE utilized the process of crowdsourcing international expertise for the clinical diagnosis of very rare genetic syndromes of multiple congenital anomalies. This is the first reported account of collaborative crowd sourcing in dysmorphology, as part of a clinical genetics service.

Keywords:
Genetic services, Access, Community genetic services, European Commission, Genetic disorders, Rare diseases
1.
Biesecker LG: Exome sequencing makes medical genomics a reality. Nat Genet 2010;42:13-14.
2.
Mette L, Mitropoulos K, Vozikis A, Patrinos GP: Pharmacogenomics and public health: implementing ‘populationalized' medicine. Pharmacogenomics 2012;13:803-813.
3.
Institute of Medicine: Genomics-Enabled Learning Health Care Systems: Gathering and Using Genomic Information to Improve Patient Care and Research: Workshop Summary. Washington, The National Academies Press, 2015.
4.
Newman WG, Black GC: Delivery of a clinical genomics service. Genes (Basel) 2014;5:1001-1017.
5.
Alzu'bi A, Zhou L, Watzlaf V: Personal genomic information management and personalized medicine: challenges, current solutions, and roles of HIM professionals. Perspect Health Inf Manag 2014;11:1c.
6.
Estellés-Arolas E, González-Ladrón-de-Guevara F: Towards an integrated crowdsourcing definition. J Inform Sci 2012;38:189-200.
7.
Howe J: Crowdsourcing. Why the Power of the Crowd Is Driving the Future of Business. New York, Crown Business, Penguin Random House Network, 2009.
8.
Majchrzak A, Malhotrac A: Towards an information systems perspective and research agenda on crowdsourcing for innovation. J Strateg Inform Syst 2013;22:257-268.
9.
Giardine B, Borg J, Higgs DR, Peterson KR, et al: Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet 2011;43:295-301.
10.
Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR: Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013;45:1160-1167.
11.
Swan M: DIY genomics crowdsourced health research studies: personal wellness and preventive medicine through collective intelligence. AAAI Technical Report SS-12-05, Self-Tracking and Collective Intelligence for Personal Wellness. Palo Alto, Association for the Advancement of Artificial Intelligence, 2011.
12.
Cooper DN, Brand A, Dolzan V, Fortina P, Innocenti F, Lee M, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Vayena E, Vozikis A, Williams MS, Patrinos GP: Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance. Pers Med 2014;11:615-623.
13.
Boudreau KJ, Lakhani KR: Using the crowd as an innovation partner. Harv Bus Rev 2013;91:60-69, 140.
14.
McCandless SE, Brunger JW, Cassidy SB: The burden of genetic disease on inpatient care in a children's hospital. Am J Hum Genet 2004;74:121-127; erratum in Am J Hum Genet 2004;74:788.
15.
Cohen MM Jr: The Child with Multiple Birth Defects, ed 2. New York, Oxford University Press, 1997.
16.
Aymé S, Rodwell C (eds): 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases, European Union Committee of Experts on Rare Diseases (EUCERD), EUCERD Joint Action: Working for Rare Diseases, No 2011 22 01. Brussels, European Union, 2012.
17.
Moeschler JB, Shevell M; the American Academy of Pediatrics Committee on Genetics: Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 2006;117:2304-2316.
18.
Douzgou S, Chervinsky E, Gyftodimou Y, Kitsiou-Tzeli S, Shalev S, Kanavakis E, Donnai D, Clayton-Smith J: Dysmorphology services: a snapshot of current practices and a vision for the future. Clin Genet DOI: 10.1111/cge.12571.
19.
Douzgou S, Clayton-Smith J; the DYSCERNE expert panel: Dysmorphology at a distance: results of a web-based diagnostic service. Eur J Hum Genet 2014;22:327-332.
20.
McAllister M, Payne K, Nicholls S, MacLeod R, Donnai D, Davies LM: Improving service evaluation in clinical genetics: identifying effects of genetic diseases on individuals and families. J Genet Couns 2007;16:71-83.
21.
Swan M: Health 2050: The realization of personalized medicine through crowdsourcing, the quantified self, and the participatory biocitizen. J Pers Med 2012;93-118.
22.
Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, et al: Global implementation of genomic medicine: we are not alone. Sci Transl Med 2015;7:290ps13.
23.
Ranard BL, Ha YP, Meisel ZF, Asch DA, Hill SS, Becker LB, Seymour AK, Merchant RM: Crowdsourcing - harnessing the masses to advance health and medicine, a systematic review. J Gen Intern Med 2014;29:187-203.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.